Showing 15 posts of 28 posts found.

American Heart Association awards $2.1m to research link between migraine, strokes and CVD

July 27, 2023
Research and Development American Heart Association, Cardiology, cvd, migraine, stroke

The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …


NHS given guidance on offering genetic testing to stroke patients

May 19, 2023
Medical Communications NHS, Neurology, blood clot, genetic testing, stroke

The NHS has been given draft guidance on offering gene tests to patients who have had a stroke caused by …


New Johnson & Johnson study aiming to add stroke detection to Apple Watch

February 26, 2020
Research and Development Apple, Janssen, Johnson & Johnson, apple watch, iphone, stroke

Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection. It …


Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019
Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …


Heart drugs show promise in stroke and dementia

April 25, 2019
Research and Development angina, cilostazol, dementia, heart drugs, isosorbide mononitrate, stroke

Drugs for heart disease and angina have shown promise as preventative treatments for stroke and dementia, according to scientists from …


China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk

January 25, 2019
Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke

Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …


Biogen halts Tysabri trial after failure in acute ischemic stroke

February 8, 2018
Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …


Incidence of strokes in younger people rising

February 1, 2018
Medical Communications biotech, drugs, pharma, pharmaceutical, stroke

On the day that a new campaign for greater awareness of stroke symptoms has been released, new figures show that …


ReNeuron’s stem cell therapy improves motor function in stroke study

December 5, 2016
Research and Development ReNeuron, stem cell, stem cell therapy, stroke

ReNeuron, a UK-based biotechnology company, posted results of its experimental stem cell therapy for patients who had been disabled after …


MSD drops osteoporosis trial drug due to stroke risk

September 5, 2016
Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke

MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …


AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients

March 23, 2016
Research and Development AstraZeneca, Brilinta, stroke

AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …


Flu jab reduces risk of stroke for two months

October 6, 2015
Research and Development flu vaccine, stroke

The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a …

Bayer image

Bayer launches major new stroke trial

January 27, 2015
Research and Development, Sales and Marketing Bayer, Canadian Stroke Prevention Intervention Network, Population Health Research Institute, Xarelto, rivaroxaban, stroke

Bayer is enrolling more than 7,000 people in a trial to test whether its blood-thinning drug Xarelto can successfully prevent …

Lundbeck scraps stroke drug

December 18, 2014
Research and Development, Sales and Marketing AIS, DIAS, Lundbeck, acute ischemic stroke, desmoteplase, stroke

Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …

Latest content